Clinical trials: Grade I Meningioma
Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment.
- Conditions
- Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma
- Trial name
- NCT02255461
- Testing
- palbociclib isethionate, pharmacological study, laboratory biomarker analysis
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma
RATIONALE: Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as…
- Trial name
- NCT00895622
- Testing
- 54 Gy radiotherapy, 60 Gy radiotherapy
- Where
- 78 sites in United States, Canada
- Volunteers
- 244 people
- Sponsor
- Radiation Therapy Oncology Group
Brain Tumors, Metastatic Disease
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
RATIONALE: Donepezil may help lessen confusion and fatigue and improve mood and quality of life in patients who have undergone radiation therapy for brain tumors.
- Trial name
- NCT00369785
- Testing
- donepezil hydrochloride
- Where
- 16 sites in United States
- Volunteers
- 198 people
- Sponsor
- Wake Forest University Health Sciences
Brain and Central Nervous System Tumors
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for recurrent glioma and meningioma.
- Trial name
- NCT00010049
- Testing
- imatinib mesylate
- Where
- 11 sites in United States
- Volunteers
- 105 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adult Meningioma
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
RATIONALE: Drugs used in chemotherapy such as hydroxyurea use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003590
- Testing
- hydroxyurea
- Where
- 133 sites in United States
- Volunteers
- 29 people
- Sponsor
- SWOG Cancer Research Network
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Meningioma, Grade I and Grade II
Ceritinib Treatment for Recurrent Meningiomas
In this study, patients with recurrent grade I and grade II meningiomas will receive a daily dose of ceritinib for abour two years. Patients will visit the clinic on average about every 2 months for assessments.
- Trial name
- CURE-M (NCT07893197)
- Testing
- Ceritinib
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Kevin Petrecca
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the safety of delivering intrathecal busulfan in children and adolescents who…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Leukemia, Lymphoma
- Trial name
- NCT00006246
- Testing
- busulfan
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pediatric Brain Tumor Consortium
Grade I Meningioma, Grade II Meningioma
Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors.
- Conditions
- Grade I Meningioma, Grade II Meningioma, Grade III Meningioma, Intracranial Neoplasm
- Trial name
- HiPPI (NCT04278118)
- Testing
- Hypofractionated Radiation Therapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Emory University
Anaplastic Astrocytoma, Anaplastic Ependymoma
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Meningioma, Anaplastic Oligodendroglioma
- Trial name
- NCT01082926
- Testing
- therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00098761
- Testing
- laromustine
- Where
- 10 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. This may be effective treatment for primary or metastatic brain tumors.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Neuroblastoma
- Trial name
- NCT00003461
- Testing
- surgical procedure, astatine At 211 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University
Adult Grade I Meningioma, Adult Grade II Meningioma
Imatinib Mesylate in Treating Patients With Recurrent Meningioma
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent meningioma. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
- Conditions
- Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Adult Meningeal Hemangiopericytoma
- Trial name
- NCT00045734
- Testing
- imatinib mesylate, laboratory biomarker analysis, pharmacological study
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer
RATIONALE: Taking part in a clinical trial may help children with cancer receive more effective treatment. PURPOSE: Determine why patients who are eligible for protocols made available through the Pediatric Oncology Group do not…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Leukemia
- Trial name
- NCT00002485
- Testing
- psychosocial assessment and care
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 359 people
- Sponsor
- Children's Oncology Group
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
Phase I trial to study the safety of combining O6-benzylguanine with temozolomide in treating children who have recurrent or refractory brain tumors.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma
- Trial name
- NCT00052780
- Testing
- O6-benzylguanine, temozolomide, filgrastim
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma
RATIONALE: Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00904735
- Testing
- hydroxyurea, imatinib mesylate
- Where
- 5 sites in Italy
- Volunteers
- 76 people
- Sponsor
- Istituto Scientifico H. San Raffaele
Brain and Central Nervous System Tumors
Studying Cerebrospinal Fluid Proteins and Angiogenesis Proteins in Young Patients With Newly Diagnosed Central Nervous System Tumors
RATIONALE: Studying samples of cerebrospinal fluid from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00897858
- Where
- 8 sites in United States
- Sponsor
- Pediatric Brain Tumor Consortium
Acoustic Schwannoma, Adult Anaplastic (Malignant) Meningioma
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
This phase I trial studies the side effects and best dose of gamma-secretase/Notch signalling pathway inhibitor RO4929097 (RO4929097) when given together with temozolomide and radiation therapy in treating patients with newly…
- Conditions
- Acoustic Schwannoma, Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
- Trial name
- NCT01119599
- Testing
- 3-Dimensional Conformal Radiation Therapy, Gamma-Secretase Inhibitor RO4929097, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of CNS tumors.
- Trial name
- NCT00025675
- Testing
- gefitinib
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma
- Trial name
- NCT00326664
- Testing
- Cediranib Maleate
- Where
- 11 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)